Where does Aska Pharmaceutical Co., Ltd. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Aska Pharmaceutical Co., Ltd. ranks #17,460 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Aska Pharmaceutical Co., Ltd. hold?

Aska Pharmaceutical Co., Ltd. holds 16 US utility patents granted between 2015 and 2023, spanning 11 technology areas.

What is Aska Pharmaceutical Co., Ltd.'s Innovation Score?

Aska Pharmaceutical Co., Ltd. has an Innovation Score of 28.9 out of 100 (29th percentile of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Aska Pharmaceutical Co., Ltd. focus on?

Aska Pharmaceutical Co., Ltd.'s top technology area is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations) with 13 patents, ranking #1,479 of 6,058 assignees active in that subclass. Grants appear in 11 CPC subclasses total.

Is Aska Pharmaceutical Co., Ltd.'s patent grant rate increasing or decreasing?

Aska Pharmaceutical Co., Ltd.'s recent grant velocity is -22% compared to the prior five-year period (grant years, not application filing dates). Grant activity has slowed relative to earlier years.

What does claim depth mean for Aska Pharmaceutical Co., Ltd.'s patents?

Aska Pharmaceutical Co., Ltd.'s patents average 8.6 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Aska Pharmaceutical Co., Ltd. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Aska Pharmaceutical Co., Ltd.

USPTO PatentsView assignee record - 16 granted patents across 11 technology areas, recorded in grant years 2015–2023. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Aska ranks #17,460 of 49,997 tracked US assignees by granted-patent volume, with 16 patents across 11 technology areas.

#17,460
of 49,997 US assignees by volume: 29th percentile
by Innovation Score (28.9/100): 8.6
avg claims per patent: -22%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R17460 · Foreign Corporation #17,460 · 16 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-FOCUS · INNOV-THIN · CLAIMS-PAR · TYPE-FRNCORP · VEL-DOWN · BOOK-FULL

GRANTS-MICRO 16 grants
MID-PACK #17,460/49,997
PHOTO-FINISH Arol S P A
CPC-FOCUS A61P · 11 areas
INNOV-THIN 28.9/100
CLAIMS-PAR 8.6 claims/avg
TYPE-FRNCORP Foreign Corp
VEL-DOWN -22% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Arol S.P.A. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Aska’s 28.9 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 9.8 pts (34%) Velocity 2.2 pts (8%) Breadth 11.7 pts (40%) Claim depth 5.2 pts (18%)

Qualcomm Incorporated · highest

85
Aska Pharmaceutical · this assignee

29
3D Lighting… · lowest

7

What this shows Aska's Innovation Score is 28.9/100 (29th percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Aska?

Each dot is one of Aska’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Aska’s own 8.6 claims/patent is at or below the 11.9 median for these volume peers. Volume here does not track with deeper claims; several lower-volume peers claim more thoroughly per patent.

Aska vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Aska's grants concentrate

Aska Pharmaceutical Co., Ltd. is a focused PatentsView assignee: 11 CPC subclasses with 81.3% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2015 (5 grants) versus a trough of 1 in 2016. By volume, Aska sits between Arol S.P.A. and AViTA Corporation.

Aska's three-year grant acceleration

Aska Pharmaceutical Co., Ltd. shows 2 grants in 2022–2024 against only 6 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Arol S P A

16
ART

16
Asahi Denso

16
Aselta Nanographi…

16
Asukanet

16
Au10tix

16
Autonomic

16
Avita

16
Aska Pharmaceutic… ◀

16

What this shows Aska holds 16 patents at rank #17,428, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Aska

By rank, the assignees closest to #17,428 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in Aska's primary technology class.

Aska's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

29 29th percentile higher than 29% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2023

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

Aska Pharmaceutical Co., Ltd. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	5	31.3%
2016	1	6.3%
2017	2	12.5%
2019	1	6.3%
2020	4	25.0%
2021	1	6.3%
2022	1	6.3%
2023	1	6.3%

Which technologies does Aska Pharmaceutical Co., Ltd. patent most?

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 13

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 8

C07D - Heterocyclic Compounds 5

C07J - Steroids 5

C07B - General Methods OF Organic CHEMISTRY; Apparatus Therefor 4

C12N - Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media 2

C07F - Acyclic, Carbocyclic OR Heterocyclic Compounds Containing Elements Other Than Carbon, Hydrogen, Halogen, Oxygen, Nitrogen, Sulfur, Selenium OR Tellurium 1

G01N - Investigating OR Analysing Materials BY Determining Their Chemical OR Physical Properties 1

Y02A - Technologies FOR Adaptation TO Climate Change 1

A61M - Devices FOR Introducing Media Into, OR Onto, THE Body ; Devices FOR Transducing Body Media OR FOR Taking Media From THE Body ; Devices FOR Producing OR Ending Sleep OR Stupor 1

C30B - Single-crystal Growth ; Unidirectional Solidification OF Eutectic Material OR Unidirectional Demixing OF Eutectoid MATERIAL; Refining BY Zone-melting OF Material ; Production OF A Homogeneous Polycrystalline Material With Defined Structure ; Single Crystals OR Homogeneous Polycrystalline Material WI 1

Top 11 of 11 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Aska Pharmaceutical Co., Ltd.'s patent record in context - here's where to go next.

Aska Pharmaceutical Co., Ltd.'s lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 81.3% of its portfolio - see every assignee active in that class. Explore A61P
Ranked #17,460 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Aska Pharmaceutical Co., Ltd. against Arol S.P.A., an assignee filing at a similar volume. Compare portfolios
Innovation Score of 28.9/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.